EP1175405A4 - INHIBITEURS LACTAME DU FACTEUR Xa ET METHODE ASSOCIEE - Google Patents

INHIBITEURS LACTAME DU FACTEUR Xa ET METHODE ASSOCIEE

Info

Publication number
EP1175405A4
EP1175405A4 EP00904564A EP00904564A EP1175405A4 EP 1175405 A4 EP1175405 A4 EP 1175405A4 EP 00904564 A EP00904564 A EP 00904564A EP 00904564 A EP00904564 A EP 00904564A EP 1175405 A4 EP1175405 A4 EP 1175405A4
Authority
EP
European Patent Office
Prior art keywords
fxa
lactam inhibitors
lactam
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00904564A
Other languages
German (de)
English (en)
Other versions
EP1175405A1 (fr
Inventor
Gregory S Bisacchi
Steven M Seiler
R Michael Lawrence
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of EP1175405A1 publication Critical patent/EP1175405A1/fr
Publication of EP1175405A4 publication Critical patent/EP1175405A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP00904564A 1999-02-09 2000-01-27 INHIBITEURS LACTAME DU FACTEUR Xa ET METHODE ASSOCIEE Withdrawn EP1175405A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11937499P 1999-02-09 1999-02-09
US119374P 1999-02-09
PCT/US2000/001859 WO2000047563A1 (fr) 1999-02-09 2000-01-27 INHIBITEURS LACTAME DU FACTEUR Xa ET METHODE ASSOCIEE

Publications (2)

Publication Number Publication Date
EP1175405A1 EP1175405A1 (fr) 2002-01-30
EP1175405A4 true EP1175405A4 (fr) 2002-05-15

Family

ID=22384077

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00904564A Withdrawn EP1175405A4 (fr) 1999-02-09 2000-01-27 INHIBITEURS LACTAME DU FACTEUR Xa ET METHODE ASSOCIEE

Country Status (5)

Country Link
EP (1) EP1175405A4 (fr)
JP (1) JP2002536437A (fr)
AU (1) AU756174B2 (fr)
CA (1) CA2361919A1 (fr)
WO (1) WO2000047563A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6344450B1 (en) * 1999-02-09 2002-02-05 Bristol-Myers Squibb Company Lactam compounds and their use as inhibitors of serine proteases and method
NZ520588A (en) * 2000-03-21 2004-06-25 Smithkline Beecham Corp Protease inhibitors
WO2001079261A1 (fr) * 2000-04-14 2001-10-25 Corvas International, Inc. Derives de tetrahydro-azepinone servant d'inhibiteurs de la thrombine
US6544981B2 (en) * 2000-06-09 2003-04-08 Bristol-Myers Squibb Company Lactam inhibitors of factor Xa and method
US6511973B2 (en) 2000-08-02 2003-01-28 Bristol-Myers Squibb Co. Lactam inhibitors of FXa and method
WO2002080853A2 (fr) 2001-04-09 2002-10-17 Bristol-Myers Squibb Company Inhibiteurs heterocycliques fusionnes du facteur xa
GB0114004D0 (en) * 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
GB0114005D0 (en) 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
GB0127568D0 (en) * 2001-11-16 2002-01-09 Glaxo Group Ltd Chemical compounds
DK1569912T3 (en) 2002-12-03 2015-06-29 Pharmacyclics Inc 2- (2-hydroxybiphenyl-3-yl) -1h-benzoimidazole-5-carboxamidine derivatives as factor VIIa inhibitors.
US7199149B2 (en) * 2003-10-01 2007-04-03 Bristol Myers Squibb Company Monocyclic and bicyclic lactams as factor Xa inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995035311A1 (fr) * 1994-06-17 1995-12-28 Corvas International, Inc. Derives de l'acide 3-amino-2-oxo-1-piperidineacetique
WO1998016523A2 (fr) * 1996-10-11 1998-04-23 Cor Therapeutics, Inc. Inhibiteurs competitifs du facteur xa
WO2000015222A1 (fr) * 1998-09-16 2000-03-23 Bristol-Myers Squibb Company INHIBITEURS FUSIONNES DE cGMP PHOSPHODIESTERASE A BASE DE PYRIDINE

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1247698B (it) * 1990-06-21 1994-12-30 Sigma Tau Ind Farmaceuti 1-alchil-3-(acilammino)-e-caprolattami quali attivatori dei processi di apprendimento e della memoria e composizioni farmaceutiche comprendenti tali composti
GB9420763D0 (en) * 1994-10-14 1994-11-30 Glaxo Inc Acetamide derivatives
US5672598A (en) * 1995-03-21 1997-09-30 The Procter & Gamble Company Lactam-containing hydroxamic acids

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995035311A1 (fr) * 1994-06-17 1995-12-28 Corvas International, Inc. Derives de l'acide 3-amino-2-oxo-1-piperidineacetique
WO1998016523A2 (fr) * 1996-10-11 1998-04-23 Cor Therapeutics, Inc. Inhibiteurs competitifs du facteur xa
WO2000015222A1 (fr) * 1998-09-16 2000-03-23 Bristol-Myers Squibb Company INHIBITEURS FUSIONNES DE cGMP PHOSPHODIESTERASE A BASE DE PYRIDINE

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ADANG A E P ET AL: "Novel acylguanidine containing thrombin inhibitors with reduced basicity at the P1 moiety", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 8, no. 24, 15 December 1998 (1998-12-15), pages 3603 - 3608, XP004150375, ISSN: 0960-894X *
See also references of WO0047563A1 *

Also Published As

Publication number Publication date
AU756174B2 (en) 2003-01-09
EP1175405A1 (fr) 2002-01-30
CA2361919A1 (fr) 2000-08-17
WO2000047563A1 (fr) 2000-08-17
JP2002536437A (ja) 2002-10-29
AU2630000A (en) 2000-08-29

Similar Documents

Publication Publication Date Title
EP1156803A4 (fr) Inhibiteurs lactame de fxa et methode
EG23117A (en) Method and apparatus for stimulation of multiple formation inyervals
GB2358053B (en) Insert and method of installation thereof
GB2349222B (en) Method and system for electroseismic monitoring of microseismicity
GB2364054B (en) Method of amplifying quinolone-resistance-determining-regions and identifying polymorphic variants thereof
EP1228061A4 (fr) Inhibiteurs de la dipeptidyl peptidase iv; methodes de fabrication et d'utilisation desdits inhibiteurs
IL143557A0 (en) Method of and device for communication
ZA978049B (en) Lactam inhibitors of thrombin
EP1370212A4 (fr) Systeme et procede d'administration intranasale de lorazepam
IL145904A0 (en) Functionally improved battery and method of making same
GB2380836B (en) Memory system and method of using same
IL135261A (en) Footwear and its method of construction
EP1183030A4 (fr) Procede de fabrication et d'application de n-desmethylzopiclone
EP1154452A4 (fr) Relais et procede de fabrication associe
IL146769A0 (en) Method of sterilizing
EP1175405A4 (fr) INHIBITEURS LACTAME DU FACTEUR Xa ET METHODE ASSOCIEE
PL347966A1 (en) Electrode and method of making same
PL352401A1 (en) Method of making nitroguanidine and nitroenamine derivatives
PL337785A1 (en) Lining unit and method of making same
GB9924752D0 (en) Method of construction
GB0201172D0 (en) Arrangement and method of providing communication
GB2346869B (en) Improved carton and method of construction therefor
PL339287A1 (en) Method of obtaining heterocyclic compounds and novel intermediate compounds
GB9910550D0 (en) Apparatus and method of recirulating electrodeionisation
PL332676A1 (en) Method of obtaining benzidamine hydrochloride

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010910

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20020328

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 07K 5/06 A, 7A 61P 7/02 B, 7C 07D 223/06 B, 7C 07D 401/02 B, 7C 07D 403/02 B, 7A 61K 31/4427 B, 7A 61K 31/496 B, 7A 61K 31/55 B

17Q First examination report despatched

Effective date: 20030805

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20061124